Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression ...Middle East

Data demonstrated that a single administration of BRII-296 at 600 mg delivered a favorable pharmacokinetic profile and is safe and well-tolerated in healthy subjects Findings suggest BRII-296 has potential to provide a safe and effective, one-time injectable treatment option to people...

Hence then, the article about brii biosciences announces top line results from phase 1 study of brii 296 a long acting therapy in development for postpartum depression was published today ( Monday 26/09/2022 - 03:08 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression )

Also on site :

• ‘Fire Country’ Announces Major Change After Season 4 Cast Shake-Up
• Roger Waters Calls Sharon Osbourne a ‘Raging Zionist’ in Heated TV Interview
• Melissa Gilbert Begs Court to Protect 'Sweet Husband' Timothy Busfield While in Jail